

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Phospho-Akt (Ser473) (736E11) Rabbit mAb

RRID:AB_331170

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3787, RRID:AB_331170

Antibody Information

URL: http://antibodyregistry.org/AB_331170

Proper Citation: Cell Signaling Technology Cat# 3787, RRID:AB_331170

Target Antigen: Phospho-Akt (Ser473) (736E11) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-P, IHC-F. Consolidation on 9/2016: AB_331171. Info: Used By NYUIHC-466.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Akt (Ser473) (736E11) Rabbit mAb

Description: This monoclonal targets Phospho-Akt (Ser473) (736E11) Rabbit mAb

Target Organism: h, m, mouse, human

Clone ID: Clone 736E11

Antibody ID: AB_331170

Vendor: Cell Signaling Technology

Catalog Number: 3787

Alternative Catalog Numbers: 3787L, 3787S

Record Creation Time: 20250819T224341+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Akt (Ser473) (736E11) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Almazan J, et al. (2025) Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. Cell reports. Medicine, 6(2), 101943.

Mayr L, et al. (2025) Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer cell, 43(4), 740.

Lv Y, et al. (2025) IFITM2 Modulates Endocytosis Maintaining Neural Stem Cells in Developing Neocortex. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(17), e2501593.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell reports. Medicine, 6(8), 102253.

Sin SH, et al. (2024) The complete Kaposi sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice. Cell host & microbe, 32(5), 755.

Ku AT, et al. (2023) Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer prevention research (Philadelphia, Pa.), 16(2), 65.

Mancarella C, et al. (2023) Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. Cancer gene therapy, 30(9), 1285.

Gao X, et al. (2023) Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 37(4), e22880.

Verma R, et al. (2023) Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities. *Cancer research*, 83(6), 890.

Wilmott JS, et al. (2023) Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(3), 521.

Song WM, et al. (2023) Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. *iScience*, 26(2), 106064.

Lin TY, et al. (2023) Epinephrine inhibits PI3K β via the Hippo kinases. *Cell reports*, 42(12), 113535.

Steiner I, et al. (2023) Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells. *Cell reports*, 42(4), 112377.

Lin CC, et al. (2022) Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state. *Molecular cell*, 82(6), 1089.

Lee JH, et al. (2022) Alzheimer's disease protease-containing plasma extracellular vesicles transfer to the hippocampus via the choroid plexus. *EBioMedicine*, 77, 103903.

Zhao X, et al. (2022) Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. *Cancer research*, 82(11), 2185.

Chaves FM, et al. (2022) Effects of the Isolated and Combined Ablation of Growth Hormone and IGF-1 Receptors in Somatostatin Neurons. *Endocrinology*, 163(5).

Gusmao DO, et al. (2022) Increased GH Secretion and Body Growth in Mice Carrying Ablation of IGF-1 Receptor in GH-releasing Hormone Cells. *Endocrinology*, 163(11).

Carrabotta M, et al. (2022) Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. *Cancer research*, 82(4), 708.

De Bacco F, et al. (2021) ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. *Cell reports*, 36(4), 109455.